ONESOURCE
Onesource Specialty Pharma share price & financials
- Price
- ₹1,608.6
- Market cap
- ₹18.6k Cr
- Sector
- Healthcare
- Calls analysed
- 7
Onesource Specialty Pharma Limited Q1 FY27
What went well
- Revenue at INR 4,490 million, up 37% year-on-year, driven by semaglutide commercial launch and new contracts.
- EBITDA at INR 1,233 million, up 39% year-on-year and 34% sequentially, reflecting strong operational performance.
- Successful semaglutide commercialization in Canada and a significant 40% share of the generic pens market in India.
What to watch
- Temporary disruption in Dr. Reddy's supplies, though mitigated by diverse customer base and full existing capacities.
- Injectable plant shutdown for capacity expansion scheduled for Q2 FY27, lasting into Q3 FY27, which will temporarily impact production.
What Onesource Specialty Pharma Limited does
OneSource Specialty Pharma is a multi-modality contract development and manufacturing organisation (CDMO) that develops and manufactures complex pharmaceutical products for global pharmaceutical companies on a B2B, fee-for-service basis. Its offerings span biologics (microbial and mammalian drug substance), drug-device combinations (pens, cartridges, pre-filled syringes) such as GLP-1/semaglutide products, sterile injectables (vials, fill-finish) and oral technologies (soft gelatine capsules), manufactured across five regulatory-approved facilities. The business, formerly Stelis Biopharma, was formed by combining the identified CDMO and Soft Gelatin businesses carved out of Strides Pharma and now serves customers directly as well as via tolling arrangements with site operators.
Segments
- Drug-Device Combinations (DDC)
- Biologics
- Sterile Injectables
- Soft Gelatin Capsules (SGC)
- Manufacturing facilities
- 5
- Combined manufacturing area
- ~722,000 sq ft across 5 facilities
- Global customers
- 75+
- Workforce
- 1,600+ professionals
- Service offerings / modalities
- 4 (DDC, Biologics, Sterile Injectables, Soft Gelatin Capsules)
- Successful regulatory audits
- 210+ (since inception)
Guidance record · Q1 FY27
what the last two calls moved 15 tracked 1 delivered 2 missed 12 open- Net Debt Status delayed said Q3 FY25 Promised: Debt Free by end of FY27 Q1 FY27: Not mentioned.
- Annual Revenue Target on track said Q3 FY25 Promised: $400 million by FY28 Q1 FY27: Reiterated FY28 outlook of $400 million organic revenue.
- FY26 Performance Warning delivered said Q4 FY25 Promised: FY26 will be a 'transition year' with a 'tepid' H1 Q4 FY26: Full-year FY26 results confirmed the transition year warning, with revenue declining 2% and EBITDA declining 35% YoY.
All 15 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 37.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 334 | 393 | 426 | 327 | 376 +13% | 290 −26% | 428 +0% | 449 +37% |
| EBITDA | 77 | 142 | 183 | 88 | 106 +38% | 17 −88% | 92 −50% | 123 +40% |
| Net profit | -42 | -69 | 98 | 0 | 10 +124% | -89 −29% | 5 −95% | 25 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −13.6% 1Y
1Y: ₹1,842 on 10 Sept 2025 → ₹1,592.2. High ₹1,889.8 (9 Oct 2025), low ₹1,114 (29 Jan 2026).
How the price took the results
close before → close after
- Q1 FY27
- +2.1%
- 25 Jul
- Q4 FY26
- −2.2%
- 13 May
- Q3 FY26
- −19.6%
- 24 Jan
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
Revenue fell 1.7% a year over 1 year, FY25 to FY26. Operating margin narrowed to 21.3%.
| Year ending | FY25 | FY26 |
|---|---|---|
| Revenue | ₹1.4k Cr | ₹1.4k Cr |
| Operating profit | ₹466 Cr | ₹303 Cr |
| Operating margin | 32.2% | 21.3% |
| Interest | ₹166 Cr | ₹122 Cr |
| Depreciation | ₹273 Cr | ₹280 Cr |
| Net profit | ₹-19 Cr | ₹-74 Cr |
| Net margin | -1.3% | -5.2% |
| Cash from operations | ₹-68 Cr | ₹9 Cr |
| Free cash flow | ₹-196 Cr | ₹-561 Cr |
| ROCE | 6.0% | 1.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹2 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹11 Cr | ₹11 Cr |
| Reserves | ₹774 Cr | ₹1.0k Cr | ₹781 Cr | ₹392 Cr | ₹5.9k Cr | ₹5.8k Cr |
| Borrowings | ₹386 Cr | ₹1.2k Cr | ₹864 Cr | ₹562 Cr | ₹1.3k Cr | ₹1.5k Cr |
| Other liabilities | ₹96 Cr | ₹276 Cr | ₹365 Cr | ₹468 Cr | ₹814 Cr | ₹875 Cr |
| Total liabilities | ₹1.3k Cr | ₹2.4k Cr | ₹2.0k Cr | ₹1.4k Cr | ₹8.0k Cr | ₹8.2k Cr |
| Fixed assets | ₹633 Cr | ₹1.2k Cr | ₹1.4k Cr | ₹863 Cr | ₹6.3k Cr | ₹6.2k Cr |
| Capital work in progress | ₹431 Cr | ₹490 Cr | ₹334 Cr | ₹188 Cr | ₹173 Cr | ₹314 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹4 Cr | ₹20 Cr | ₹20 Cr | ₹16 Cr |
| Other assets | ₹195 Cr | ₹722 Cr | ₹314 Cr | ₹356 Cr | ₹1.5k Cr | ₹1.6k Cr |
| Total assets | ₹1.3k Cr | ₹2.4k Cr | ₹2.0k Cr | ₹1.4k Cr | ₹8.0k Cr | ₹8.2k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, the public trimmed −6.47 pp while DIIs added +5.28 pp. The shareholder count shrank 11% to 77,899.
- Promoters
- 30.5%
- FIIs
- 19.2%
- DIIs
- 23.4%
- Public
- 26.9%
Since Jun 2025
- Public −6.47 pp
- DIIs +5.28 pp
- Promoters +0.70 pp
How it drifted, 7 quarters
Over this window DIIs went from 12.6% to 23.4% — +10.8 pp.
Ownership split by quarter, oldest first. Dec '24: Promoters 37.8%, FIIs 17.4%, DIIs 12.6%, Public 32.2%.Mar '25: Promoters 34.3%, FIIs 18.5%, DIIs 18.0%, Public 29.2%.Jun '25: Promoters 29.8%, FIIs 18.7%, DIIs 18.1%, Public 33.4%.Sep '25: Promoters 29.8%, FIIs 19.4%, DIIs 18.5%, Public 32.3%.Dec '25: Promoters 29.9%, FIIs 19.2%, DIIs 18.8%, Public 32.0%.Mar '26: Promoters 30.5%, FIIs 17.5%, DIIs 20.6%, Public 31.4%.Jun '26: Promoters 30.5%, FIIs 19.2%, DIIs 23.4%, Public 26.9%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Motilal Oswal Mutual Fund Mutual fund +2.07 pp 7.06% held
- Fidelity Securities Fund: Fidelity Blue Chip Growth Fund Global fund house newly disclosed 1.76% held
The same filing shows 5 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Onesource Specialty Pharma Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Tenshi Pharmaceuticals Private Limited | 18.40% | unchanged |
| Karuna Business Solutions Llp | 7.06% | unchanged |
| Motilal Oswal Mutual Fund Mutual fund | 7.06% | +2.07 pp |
| Authum Investment And Infrastructure Limited NBFC / DFI | 4.96% | −0.20 pp |
| Pronomz Ventures Llp | 2.41% | unchanged |
| Route One Offshore Master Fund L.P. FPI fund | 2.32% | unchanged |
| Route One Fund I, L.P. FPI fund | 2.07% | unchanged |
| SBI Life Insurance Co. Ltd Insurer | 2.06% | −0.47 pp |
| Amansa Holdings Private Limited FPI fund | 1.86% | −1.61 pp |
| Think Investments Pcc FPI fund | 1.79% | unchanged |
| Fidelity Securities Fund: Fidelity Blue Chip Growth Fund Global fund house | 1.76% | newly disclosed |
| 360 One Special Opportunities Fund - Series 12 Mutual fund | 1.62% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Mutual funds in ONESOURCE
Filings to Aug 2026
0 new, 4 added, 1 trimmed, 0 sold out — net +0.02 L shares (+1.1%).
- Held by funds
- ₹30 Cr
- 5 schemes
- Biggest holder
- Nippon India Nifty Smallcap 250 Index Fund
- ₹19 Cr · 0.5% of that fund
| Scheme | Holding | Last month | Held since |
|---|---|---|---|
| Nippon India Nifty Smallcap 250 Index Fund Nippon India Mutual Fund | ₹19 Cr | +0.02 L | Sep '25 |
| SBI Nifty Smallcap 250 Index Fund SBI Mutual Fund | ₹10 Cr | +0.01 L | Oct '25 |
| Nippon India Nifty 500 Equal Weight Index Fund Nippon India Mutual Fund | ₹1 Cr | +0.00 L | Sep '25 |
| SBI Nifty 500 Index Fund SBI Mutual Fund | ₹0 Cr | −0.00 L | Oct '25 |
| SBI Nifty Small Cap 250 ETF SBI Mutual Fund | ₹0 Cr | +0.00 L | May '26 |
HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.
Mutual funds Aug 2026
4 added, 1 trimmed — net +2,245 shares (+1.1%)
- Funds are sitting on
- -8%
- vs est. average cost
- Held by funds
- ₹30 Cr
- 5 schemes · ≈ 0.17% of the company
- Biggest holder
- Nippon India Nifty Smallcap 250 Index Fund
- ₹19 Cr · 0.5% of that fund
Shares held by these funds +158%
Sep '25 1.97 L shares Jul '26
All earnings calls (6)
Read the Q1 FY27 call →Learn to analyse Onesource Specialty Pharma Limited
Guides on how to read this kind of business and the numbers that matter.